NCT06512428View on ClinicalTrials.gov

A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

January 30, 2026

Study Completion Date

January 30, 2026

Conditions
Advanced Esophageal Squamous Cell Carcinoma
Interventions
DRUG

simmitinib plus irinotecan liposome

simmitinib plus irinotecan liposome 70 mg/m\^2 every 2 weeks

DRUG

irinotecan liposome

irinotecan liposome 70 mg/m\^2 every 2 weeks

DRUG

irinotecan

irinotecan 180mg/m\^2 every 2 weeks

Trial Locations (1)

150076

RECRUITING

Harbin Medical University Cancer Hospital, Heilongjiang

All Listed Sponsors
lead

Shanghai Runshi Pharmaceutical Technology Co., Ltd

INDUSTRY